This limited clinical efficacy may be due to insufficient target inhibition, which might be overcome by combining MEK and ERK inhibitors, a treatment modality that induces better responses than either agent alone in NRAS-mutant melanoma in vitro (Rebecca et al., 2014). Here, NRAS is linked to melanoma.